Antonini Angelo, Robieson Weining Z, Bergmann Lars, Yegin Ashley, Poewe Werner
Department of Neuroscience, Padua University, Padua, 35122, Italy.
AbbVie, Inc., North Chicago, IL 60064, USA.
Neurodegener Dis Manag. 2018 Jun;8(3):161-170. doi: 10.2217/nmt-2017-0046. Epub 2018 Apr 10.
To determine if age and Parkinson's disease duration at therapy initiation influence the efficacy of levodopa-carbidopa intestinal gel (LCIG) on quality of life and activities of daily living.
PATIENTS & METHODS: This post hoc analysis assessed subgroups of patients stratified by baseline age, disease duration, hours/day of 'off' time and levodopa equivalent dose. Patients' data were collected from the GLORIA study, a 24-month observational registry evaluating long-term effectiveness of LCIG.
RESULTS & CONCLUSION: LCIG therapy led to sustained improvements in quality of life irrespective of patient age and disease duration at baseline. Improvements in activities of daily living were observed across all subgroups, particularly in younger patients, patients with shorter disease duration and in patients with the highest baseline levodopa equivalent dose.
确定治疗开始时的年龄和帕金森病病程是否会影响左旋多巴-卡比多巴肠凝胶（LCIG）对生活质量和日常生活活动的疗效。
这项事后分析评估了按基线年龄、病程、每日“关”期时长和左旋多巴等效剂量分层的患者亚组。患者数据来自GLORIA研究，这是一项评估LCIG长期疗效的为期24个月的观察性登记研究。
无论患者基线年龄和病程如何，LCIG治疗均能持续改善生活质量。所有亚组的日常生活活动均有改善，尤其是年轻患者、病程较短的患者以及基线左旋多巴等效剂量最高的患者。
